Another work in non-small cell lung cancer (NSCLC) is in line with these findings, showing that patients with low Gal-9 levels on tumour cells or high Gal-9 on tumour-infiltrating lymphocytes (TILs), as seen with immunohistochemistry, were more likely to have poor prognosis (44). This evidence concerns the gene LGALS9 and neoplasm.